These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

776 related articles for article (PubMed ID: 31873309)

  • 1. Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma.
    Goswami S; Walle T; Cornish AE; Basu S; Anandhan S; Fernandez I; Vence L; Blando J; Zhao H; Yadav SS; Ott M; Kong LY; Heimberger AB; de Groot J; Sepesi B; Overman M; Kopetz S; Allison JP; Pe'er D; Sharma P
    Nat Med; 2020 Jan; 26(1):39-46. PubMed ID: 31873309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting CD73 limits tumor progression and enhances anti-tumor activity of anti-PD-1 therapy in intrahepatic cholangiocarcinoma.
    Sun BY; Zhang D; Gan W; Wu JF; Wang ZT; Sun GQ; Zhou J; Fan J; Yi Y; Hu B; Zhang BH; Qiu SJ
    J Cancer Res Clin Oncol; 2024 Jul; 150(7):348. PubMed ID: 39002018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.
    Allard B; Pommey S; Smyth MJ; Stagg J
    Clin Cancer Res; 2013 Oct; 19(20):5626-35. PubMed ID: 23983257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intratumoral CD73: An immune checkpoint shaping an inhibitory tumor microenvironment and implicating poor prognosis in Chinese melanoma cohorts.
    Gao Z; Wang L; Song Z; Ren M; Yang Y; Li J; Shen K; Li Y; Ding Y; Yang Y; Zhou Y; Wei C; Gu J
    Front Immunol; 2022; 13():954039. PubMed ID: 36131912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specific blockade CD73 alters the "exhausted" phenotype of T cells in head and neck squamous cell carcinoma.
    Deng WW; Li YC; Ma SR; Mao L; Yu GT; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
    Int J Cancer; 2018 Sep; 143(6):1494-1504. PubMed ID: 29663369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nasal Administration of Cationic Nanoemulsions as CD73-siRNA Delivery System for Glioblastoma Treatment: a New Therapeutical Approach.
    Azambuja JH; Schuh RS; Michels LR; Gelsleichter NE; Beckenkamp LR; Iser IC; Lenz GS; de Oliveira FH; Venturin G; Greggio S; daCosta JC; Wink MR; Sevigny J; Stefani MA; Battastini AMO; Teixeira HF; Braganhol E
    Mol Neurobiol; 2020 Feb; 57(2):635-649. PubMed ID: 31407144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blockade of CD73 delays glioblastoma growth by modulating the immune environment.
    Azambuja JH; Schuh RS; Michels LR; Iser IC; Beckenkamp LR; Roliano GG; Lenz GS; Scholl JN; Sévigny J; Wink MR; Stefani MA; Battastini AMO; Figueiró F; Teixeira HF; Braganhol E
    Cancer Immunol Immunother; 2020 Sep; 69(9):1801-1812. PubMed ID: 32350590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model.
    Reardon DA; Gokhale PC; Klein SR; Ligon KL; Rodig SJ; Ramkissoon SH; Jones KL; Conway AS; Liao X; Zhou J; Wen PY; Van Den Abbeele AD; Hodi FS; Qin L; Kohl NE; Sharpe AH; Dranoff G; Freeman GJ
    Cancer Immunol Res; 2016 Feb; 4(2):124-35. PubMed ID: 26546453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD73 and PD-L1 as Potential Therapeutic Targets in Gallbladder Cancer.
    Cao L; Bridle KR; Shrestha R; Prithviraj P; Crawford DHG; Jayachandran A
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autocrine Adenosine Regulates Tumor Polyfunctional CD73
    Gourdin N; Bossennec M; Rodriguez C; Vigano S; Machon C; Jandus C; Bauché D; Faget J; Durand I; Chopin N; Tredan O; Marie JC; Dubois B; Guitton J; Romero P; Caux C; Ménétrier-Caux C
    Cancer Res; 2018 Jul; 78(13):3604-3618. PubMed ID: 29559470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An overview of current therapeutic strategies for glioblastoma and the role of CD73 as an alternative curative approach.
    Arab S; Hasannejad F
    Clin Transl Oncol; 2022 May; 24(5):742-756. PubMed ID: 34792724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastoma.
    Simonds EF; Lu ED; Badillo O; Karimi S; Liu EV; Tamaki W; Rancan C; Downey KM; Stultz J; Sinha M; McHenry LK; Nasholm NM; Chuntova P; Sundström A; Genoud V; Shahani SA; Wang LD; Brown CE; Walker PR; Swartling FJ; Fong L; Okada H; Weiss WA; Hellström M
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34083417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic immunotherapy of glioblastoma by dual targeting of IL-6 and CD40.
    Yang F; He Z; Duan H; Zhang D; Li J; Yang H; Dorsey JF; Zou W; Nabavizadeh SA; Bagley SJ; Abdullah K; Brem S; Zhang L; Xu X; Byrne KT; Vonderheide RH; Gong Y; Fan Y
    Nat Commun; 2021 Jun; 12(1):3424. PubMed ID: 34103524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD73 acts as a prognostic biomarker and promotes progression and immune escape in pancreatic cancer.
    Chen Q; Pu N; Yin H; Zhang J; Zhao G; Lou W; Wu W
    J Cell Mol Med; 2020 Aug; 24(15):8674-8686. PubMed ID: 32643277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of Small and Bifunctional Molecules Targeting PD-L1/CD73 for Cancer Dual Immunotherapy.
    Wang S; Kong Z; Shi Y; Shao C; Wang W; Su Z; Liu J; Zhou Y; Fei X; Cheng B; Chen J; Lu Y; Xiao J
    J Med Chem; 2024 Jun; 67(11):9447-9464. PubMed ID: 38748913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual Mechanisms of Novel CD73-Targeted Antibody and Antibody-Drug Conjugate in Inhibiting Lung Tumor Growth and Promoting Antitumor Immune-Effector Function.
    Jin R; Liu L; Xing Y; Meng T; Ma L; Pei J; Cong Y; Zhang X; Ren Z; Wang X; Shen J; Yu K
    Mol Cancer Ther; 2020 Nov; 19(11):2340-2352. PubMed ID: 32943546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methotrexate up-regulates ecto-5'-nucleotidase/CD73 and reduces the frequency of T lymphocytes in the glioblastoma microenvironment.
    Figueiró F; de Oliveira CP; Bergamin LS; Rockenbach L; Mendes FB; Jandrey EH; Moritz CE; Pettenuzzo LF; Sévigny J; Guterres SS; Pohlmann AR; Battastini AM
    Purinergic Signal; 2016 Jun; 12(2):303-12. PubMed ID: 26910734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD73 as a potential opportunity for cancer immunotherapy.
    Ghalamfarsa G; Kazemi MH; Raoofi Mohseni S; Masjedi A; Hojjat-Farsangi M; Azizi G; Yousefi M; Jadidi-Niaragh F
    Expert Opin Ther Targets; 2019 Feb; 23(2):127-142. PubMed ID: 30556751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD73 on cancer-associated fibroblasts enhanced by the A
    Yu M; Guo G; Huang L; Deng L; Chang CS; Achyut BR; Canning M; Xu N; Arbab AS; Bollag RJ; Rodriguez PC; Mellor AL; Shi H; Munn DH; Cui Y
    Nat Commun; 2020 Jan; 11(1):515. PubMed ID: 31980601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the PD-1/PD-L1 pathway in glioblastoma multiforme: Preclinical evidence and clinical interventions.
    Maghrouni A; Givari M; Jalili-Nik M; Mollazadeh H; Bibak B; Sadeghi MM; Afshari AR; Johnston TP; Sahebkar A
    Int Immunopharmacol; 2021 Apr; 93():107403. PubMed ID: 33581502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.